Rohto Pharmaceutical raised its 2030 sales and operating profit targets on 2 October but cut the margin it expects to earn on them. The company also added 2031 as the new end-point of its rolling plan and set a higher payout goal.
What moved
The earlier plan, published in 2025, aimed for 2030 sales of ¥415.0bn, operating profit of ¥54.0bn, a 13% operating margin and an 18.2% EBITDA margin. The rolling update changes those to ¥444.0bn, ¥56.8bn, 12.8% and 18.0%. The company's presentation also lifts the overseas sales ratio target for 2030 to 56% from 53%.
For 2027, the presentation shows sales of ¥390.0bn and operating profit of ¥48.7bn, up from ¥365.0bn and ¥46.0bn in the original plan.
The new 2031 targets are sales of ¥464.0bn, operating profit of ¥59.8bn, a 12.9% margin, a 56% overseas ratio and a 40% dividend payout ratio. The release does not explain why the margin goal is lower than before.
| Fiscal year | Sales | Operating profit (margin) | Overseas sales ratio | Payout ratio |
|---|---|---|---|---|
| 2025 | ¥343.7bn | ¥41.1bn (12.0%) | 51% | 30.4% |
| 2028 | ¥405.0bn | ¥51.0bn (12.6%) | 54% | 36% |
| 2031 | ¥464.0bn | ¥59.8bn (12.9%) | 56% | 40% |
Payout and longer-term goals
The previous plan assumed a payout ratio of at least 30% and a dividend on equity (DOE) ratio of at least 3.5%. The 2031 goal is a 40% payout ratio and DOE of at least 4.0%. Rohto's payout ratio was 30.4% in the 2025 fiscal year.
The presentation also sets 2035 sales ranges by business: ¥300–320bn for skincare, ¥85–100bn for oral and food products (excluding prescription-drug contract operations), ¥60–80bn for medical, and ¥70–80bn for eye care excluding prescription products.
These are targets in a plan the company says it will keep revising on a rolling basis.